+

WO1994008551A3 - Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume - Google Patents

Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume Download PDF

Info

Publication number
WO1994008551A3
WO1994008551A3 PCT/US1993/008887 US9308887W WO9408551A3 WO 1994008551 A3 WO1994008551 A3 WO 1994008551A3 US 9308887 W US9308887 W US 9308887W WO 9408551 A3 WO9408551 A3 WO 9408551A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
methods
cold
cold symptoms
treating cold
Prior art date
Application number
PCT/US1993/008887
Other languages
English (en)
Other versions
WO1994008551A2 (fr
Inventor
James Grigg Upson
Carmelita Macklin Russell
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to JP6510004A priority Critical patent/JPH08502288A/ja
Priority to AU49307/93A priority patent/AU678561B2/en
Priority to EP93921692A priority patent/EP0662840A1/fr
Priority to CA002146637A priority patent/CA2146637C/fr
Publication of WO1994008551A2 publication Critical patent/WO1994008551A2/fr
Publication of WO1994008551A3 publication Critical patent/WO1994008551A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Compositions pharmaceutiques comprenant une dose sûre et efficace d'au moins un produit pharmaceutique agissant contre le rhume; 3-1-menthoxy propane 1,2-diol; et un excipient pharmaceutiquement acceptable convenant à une administration orale ou nasale. La présente invention se rapporte également à des procédés de traitement de la toux, du rhume, des allergies, de symptômes analogues au rhume et/ou de symptômes grippaux chez l'homme ou l'animal. Ce procédé consiste à administrer à un homme ou un animal nécessitant un tel traitement, par voie orale ou nasale, une composition comprenant 3-1-menthoxy propane 1,2-diol.
PCT/US1993/008887 1992-10-09 1993-09-22 Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume WO1994008551A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6510004A JPH08502288A (ja) 1992-10-09 1993-09-22 感昌症状を治療するための医薬組成物及び用法
AU49307/93A AU678561B2 (en) 1992-10-09 1993-09-22 Pharmaceutical compositions and methods for treating cold symptoms
EP93921692A EP0662840A1 (fr) 1992-10-09 1993-09-22 Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume
CA002146637A CA2146637C (fr) 1992-10-09 1993-09-22 Compositions pharmaceutiques et methodes pour traiter les symptomes du rhume

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95501392A 1992-10-09 1992-10-09
US07/955,013 1992-10-09

Publications (2)

Publication Number Publication Date
WO1994008551A2 WO1994008551A2 (fr) 1994-04-28
WO1994008551A3 true WO1994008551A3 (fr) 1994-06-23

Family

ID=25496254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008887 WO1994008551A2 (fr) 1992-10-09 1993-09-22 Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume

Country Status (7)

Country Link
EP (1) EP0662840A1 (fr)
JP (1) JPH08502288A (fr)
AU (1) AU678561B2 (fr)
CA (1) CA2146637C (fr)
MX (1) MX9306295A (fr)
NZ (1) NZ256346A (fr)
WO (1) WO1994008551A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078066B2 (en) 1997-09-18 2006-07-18 Wm. Wrigley Jr. Company Chewing gum containing physiological cooling agents and method of making

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500610A (ja) * 1993-04-30 1997-01-21 ザ、プロクター、エンド、ギャンブル、カンパニー 経鼻芳香放出組成物
WO1995025518A1 (fr) * 1994-03-18 1995-09-28 Ciba-Geigy Ag Solution aqueuse de levocabastine a usage ophtalmique
US5698181A (en) * 1994-12-09 1997-12-16 Warner-Lambert Company Breath-freshening edible compositions comprising menthol and an N-substituted-P-menthane carboxamide and methods for preparing same
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
GB9707977D0 (en) * 1997-04-21 1997-06-11 Procter & Gamble Centre filled confectionery
GB9707978D0 (en) * 1997-04-21 1997-06-11 Procter & Gamble Throat soothing compositions
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IL160539A0 (en) * 2001-09-04 2004-07-25 Boehringer Ingelheim Int Anti-influenzal agents
ES2298540T3 (es) 2002-04-04 2008-05-16 Pfizer Products Inc. Comprimido masticable agradable.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20090203776A1 (en) * 2004-09-23 2009-08-13 Matias Jonathan R Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
AU2016219620B2 (en) * 2006-04-21 2017-05-11 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
EP2714021A1 (fr) * 2011-02-02 2014-04-09 Max Reynolds Composition de monoterpénoïdes à propriétés bactéricides
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CA3100314A1 (fr) 2018-05-16 2019-11-21 Bayer Healthcare Llc Formulation de suspension a concentration elevee pour medicaments a capsule molle contre le rhume et la grippe
CN112972439A (zh) * 2019-12-16 2021-06-18 南京亿华药业有限公司 一种愈美泡腾片及其制备方法
MX2022009557A (es) 2020-02-03 2022-11-14 Johnson & Johnson Consumer Inc Un comprimido masticable de una sola capa que comprende cetirizina.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2127011A1 (fr) * 1971-02-04 1972-10-13 Wilkinson Sword Ltd
WO1992017164A1 (fr) * 1991-04-04 1992-10-15 The Procter & Gamble Company Compositions pharmaceutiques administrees par voie buccale dans le traitement de troubles de la partie superieure des voies gastro-intestinales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5888334A (ja) * 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2127011A1 (fr) * 1971-02-04 1972-10-13 Wilkinson Sword Ltd
WO1992017164A1 (fr) * 1991-04-04 1992-10-15 The Procter & Gamble Company Compositions pharmaceutiques administrees par voie buccale dans le traitement de troubles de la partie superieure des voies gastro-intestinales

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078066B2 (en) 1997-09-18 2006-07-18 Wm. Wrigley Jr. Company Chewing gum containing physiological cooling agents and method of making

Also Published As

Publication number Publication date
AU4930793A (en) 1994-05-09
EP0662840A1 (fr) 1995-07-19
JPH08502288A (ja) 1996-03-12
MX9306295A (es) 1994-04-29
WO1994008551A2 (fr) 1994-04-28
AU678561B2 (en) 1997-06-05
NZ256346A (en) 1997-04-24
CA2146637C (fr) 2001-02-13

Similar Documents

Publication Publication Date Title
WO1994008551A3 (fr) Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
DK0799024T3 (da) Farmaceutisk aerosol indeholdende mindst en sukker
CA2125665A1 (fr) Medicaments
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
HK1003978A1 (en) Composition for the treatment of schizophrenia
SG166294G (en) Inhalation medicaments for treating respiratory disorders
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
WO2003024387A3 (fr) Methode et composition pharmaceutique destinees au traitement d'inflammations
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
NO952906L (no) Farmasöytisk formulering for behandling av nikotinavhengighet
GR3015934T3 (en) Reduction or prevention of skin irritation by drugs.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
CA2120062A1 (fr) Utilisation de sulodexide et de medicaments en contenant dans le traitement de la nephropathie diabetique
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
HK1068606A1 (en) Novel aminobenzoephenones
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
GB8928609D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO NZ RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO NZ RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 256346

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2146637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993921692

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993921692

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993921692

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载